Machine vision technology ensures 100% surface inspection and zero-blind-spot quality control for tablets and capsules.
Seoul, South Korea, 15th Oct 2026 – As pharmaceutical manufacturing processes become increasingly automated and production speeds rise, automated visual inspection (AVI) is becoming essential for ensuring the quality of tablets and capsules.
Visual inspection in pharmaceutical production goes beyond checking product appearance. During manufacturing, tablets and capsules can develop various defects, including chipping, cracks, foreign matter, discoloration, coating irregularities, and printing errors. Detecting these defects before shipment and selecting only compliant products is a vital step in pharmaceutical quality management.
Above all, this process is crucial for patient safety. Broken or chipped tablets and capsules with compromised contents do not represent acceptable product quality. Foreign matter or contamination poses severe hygiene and safety concerns, while cracked or peeling coatings can directly impact drug efficacy. For enteric-coated or sustained-release formulations designed to control the release site and rate of active ingredients, coating integrity is directly linked to product function. Defective coating may cause active ingredients to release too quickly or too slowly, affecting both safety and therapeutic outcomes. Therefore, visual inspection is a necessary quality assurance process to ensure patients receive medications that meet intended performance standards.
From a manufacturer’s perspective, consistent quality builds corporate and brand trust. Pharmaceutical companies exporting to international markets must stably meet quality standards across different regions. Defective products reaching the market can cause customer complaints, costly recalls, returns, and loss of business trust, making pre-shipment screening vital.
ENCLONY Co., Ltd., a specialist in automated pharmaceutical inspection systems, utilizes machine vision technology that captures and analyzes the entire surface of tablets and capsules from multiple angles. The system inspects top, bottom, and side surfaces of tablets, as well as the cylindrical body and ends of capsules, eliminating blind spots to identify defects such as chipping, contamination, discoloration, and coating or printing flaws.
Using algorithms that step-by-step learn normal product characteristics, ENCLONY sets inspection criteria tailored to each product. To prevent defect-identified items from mixing into compliant batches, the company applies a patented Triple Checking System. This technology re-verifies the removal of rejected items after sorting, ensuring defective products are reliably separated.
In terms of throughput, ENCLONY’s PLANET EV model can inspect up to 425,000 tablets per hour, while the high-speed PLANET EVS model processes up to 600,000 tablets per hour, enabling complete, 100% inspection even in high-volume production environments.
“For pharmaceutical companies, consistent quality is a key factor in building corporate trust, and for patients, it directly impacts receiving safe, reliable medications,” stated Kyung-Ho Lee, CEO of ENCLONY. “As production speeds increase, the importance of automated visual inspection technology that can evaluate every item against identical standards will continue to grow.”
Lee added, “ENCLONY plans to continuously advance its machine vision and automated inspection technologies to stably inspect full product surfaces and accurately sort defects, even in high-speed manufacturing environments.”
ENCLONY develops and supplies comprehensive automated inspection solutions for pharmaceutical manufacturing, including automated visual inspection systems for tablets and capsules, integrated laser printing and inspection systems, and containment inspection systems for high-potency active pharmaceutical ingredients (HPAPIs).
[About ENCLONY Co., Ltd.] ENCLONY Co., Ltd. is a South Korea-based technology leader specializing in automated visual inspection and laser printing systems for the pharmaceutical manufacturing industry.
For more information, please visit http://www.enclony.com
Media Contact
Organization: ENCLONY Co., Ltd.
Contact Person: Young-Mi Cho
Website: http://www.enclony.com
Email: Send Email
City: Seoul
Country: South Korea
Release id: 49942
View source version on King Newswire:
ENCLONY Expands Automated Visual Inspection Tech as Pharmaceutical Production Speeds Accelerate